Home LiteratureArticle Details
PMID: 11996681 Published · ppublish English Journal Article

Trends in fluoroquinolone (ciprofloxacin) resistance in enterobacteriaceae from bacteremias, England and Wales, 1990-1999.

Emerging infectious diseases ·Vol. 8 ·No. 5 ·2002-05-00 ·Pages 473-8

Livermore DM, James D, Reacher M, Graham C, Nichols T, Stephens P, Johnson AP, George RC

Abstract

The Public Health Laboratory Service receives antibiotic susceptibility data for bacteria from bloodstream infections from most hospitals in England and Wales. These data were used to ascertain resistance trends to ciprofloxacin from 1990 through 1999 for the most prevalent gram-negative agents: Escherichia coli, Klebsiella spp., Enterobacter spp., and Proteus mirabilis. Significant increases in resistance were observed for all four species groups. For E. coli, ciprofloxacin resistance rose from 0.8% in 1990 to 3.7% in 1999 and became widely scattered among reporting hospitals. The prevalence of resistance in Klebsiella spp. rose from 3.5% in 1990, to 9.5% in 1996 and 7.1% in 1999, while that in Enterobacter spp. rose from 2.1% in 1990 to 10.5% in 1996 and 10.9% in 1999. For both Klebsiella and Enterobacter spp., most resistance was localized in a few centers. Resistance was infrequent and scattered in P. mirabilis, but reached a prevalence of 3.3% in 1999.

MeSH Terms
Bacteremia/drug therapy,microbiology Ciprofloxacin/pharmacology,therapeutic use Drug Resistance, Bacterial Drug Utilization England/epidemiology Enterobacteriaceae/drug effects,physiology Enterobacteriaceae Infections/drug therapy,microbiology Fluoroquinolones/pharmacology,therapeutic use Humans Practice Patterns, Physicians' Wales/epidemiology
Chemicals
Fluoroquinolones Ciprofloxacin
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Livermore David M
Antibiotic Resistance Monitoring and Reference Laboratory, Central Public Health Laboratory, 61 Colindale Avenue, London NW9 5HT, UK. DLivermore@phls.nhs.uk
James Dorothy
Reacher Mark
Graham Catriona
Nichols Thomas
Stephens Peter
Johnson Alan P
George Robert C
References (17)
17 references, click to expand
  1. Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center.
    Antimicrob Agents Chemother. 1994 Apr;38(4):681-7 PMID: 8031031
  2. Contributions of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals.
    Antimicrob Agents Chemother. 1996 Oct;40(10):2380-6 PMID: 8891148
  3. Molecular epidemiological analysis of quinolone-resistant Escherichia coli causing bacteremia in neutropenic patients with leukemia in Korea.
    Clin Infect Dis. 1997 Dec;25(6):1385-91 PMID: 9431383
  4. Emerging bacterial drug resistance in hospital practice.
    Indian J Med Sci. 1997 Aug;51(8):275-80 PMID: 9491681
  5. Quinolone resistance from a transferable plasmid.
    Lancet. 1998 Mar 14;351(9105):797-9 PMID: 9519952
  6. Antibiotic resistance in Escherichia coli isolated from blood and cerebrospinal fluid: a 6-year study of isolates from patients in England and Wales.
    Int J Antimicrob Agents. 1997 Jan;9(3):201-5 PMID: 9552717
  7. Multiresistant bacteria as a hospital epidemic problem.
    Ann Med. 1998 Apr;30(2):176-85 PMID: 9667796
  8. Colonization and infection with fluoroquinolone-resistant Escherichia coli among cancer patients: clonal analysis.
    Infection. 1998 Nov-Dec;26(6):379-84 PMID: 9861564
  9. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria.
    Clin Infect Dis. 1999 Sep;29(3):490-4 PMID: 10530434
  10. Emergence and dissemination of quinolone-resistant Escherichia coli in the community.
    Antimicrob Agents Chemother. 1999 Nov;43(11):2736-41 PMID: 10543756
  11. Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin.
    J Med Chem. 1999 Dec 2;42(24):4928-31 PMID: 10585202
  12. Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis.
    BMJ. 2000 Jan 22;320(7229):213-6 PMID: 10642227
  13. Are routine sensitivity test data suitable for the surveillance of resistance? Resistance rates amongst Escherichia coli from blood and CSF from 1991-1997, as assessed by routine and centralized testing.
    J Antimicrob Chemother. 2000 Feb;45(2):205-11 PMID: 10660502
  14. In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid.
    Eur J Clin Microbiol. 1983 Apr;2(2):111-5 PMID: 6222896
  15. The mode of action of 4-quinolones and possible mechanisms of resistance.
    J Antimicrob Chemother. 1986 Nov;18 Suppl D:21-9 PMID: 3542946
  16. A guide to sensitivity testing. Report of the Working Party on Antibiotic Sensitivity Testing of the British Society for Antimicrobial Chemotherapy.
    J Antimicrob Chemother. 1991 Jun;27 Suppl D:1-50 PMID: 1874686
  17. Use of the quinolones for the prophylaxis and therapy of infections in immunocompromised hosts.
    Drugs. 1993;45 Suppl 3:73-80 PMID: 7689455
Article Info
Journal
Emerging infectious diseases
Abbr.
Emerg Infect Dis
ISSN
1080-6040
Published
2002-05-00
Pages
473-8
Language
English
Region
United States
NLM ID
9508155
PMCID
PMC2732494
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com